Market Overview

Biogen to Present at the 2018 Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD) Focus Meeting

  • Data builds on Biogen's core work in Alzheimer's disease and movement
    disorders such as Parkinson's disease and progressive supranuclear
  • New aducanumab Phase 1b amyloid imaging analysis on the Centiloid scale
  • Biogen research programs target several of the identified causes of
    Alzheimer's disease with an emphasis on early-stage disease

(NASDAQ:BIIB) will present data from its portfolio of investigational
therapies for people with neurodegenerative diseases at the Advances in
Alzheimer's and Parkinson's Therapies (AAT-AD/PD) Focus Meeting in
Torino, Italy (March 15-18, 2018). AAT-AD/PD is a new joint meeting
between the International Geneva/Springfield Symposium on Advances in
Alzheimer's Therapy and AD/PD™.

Alessandro Padovani M.D., Ph.D., professor of neurology and director of
the Institute of Neurology at the Università degli Studi di Brescia,
will open the meeting discussing the importance of early identification
and treatment of Alzheimer's disease. His discussion will include
Centiloid, a method used to standardize the aducanumab Phase 1b study
amyloid PET results as previously measured by the composite Standardized
Uptake Value Ratio (SUVR). At 54 weeks, the treatment group receiving
the highest dose of aducanumab (10 mg/kg) experienced a 69% reduction
from baseline in amyloid plaque as observed on the Centiloid Conversion
scale (P<0.001 versus placebo). There was no change from baseline in the
placebo arm.

In the Phase 1b long-term extension (LTE), the most commonly reported
adverse events were headache, fall, and amyloid-related imaging
abnormalities (ARIA). Of the 185 patients dosed with aducanumab in the
Phase 1b study, 46 patients experienced ARIA-E (edema). There were no
new cases of ARIA-E in patients who continued on the same dose of

"Biogen is working to solve some of medicine's greatest challenges among
the most complex, devastating neurodegenerative diseases," said Alfred
Sandrock, M.D., Ph.D., executive vice president and chief medical
officer at Biogen. "As pioneers in neuroscience with 40 years of
expertise we remain committed to tackling areas of high unmet medical
need such as Alzheimer's disease and movement disorders including
Parkinson's disease and progressive supranuclear palsy."

The planned Alzheimer's disease presentations include:

  • The Importance of Early Identification and Treatment of Alzheimer's
    Plenary Session; March 15, 2018, 13:00 – 13:30 CET.
  • The early diagnosis of Alzheimer's disease: It's about time.
    Biogen Sponsored Symposium; March 16, 2018, 11:45 – 13:25 CET.
  • Aducanumab interim analysis from PRIME: A randomized, double-blind,
    placebo-controlled Phase 1B study in patients with prodromal or mild
    Alzheimer's disease
    . Symposium Session 13; March 16, 2018, 16:45 –
    17:05 CET.

The planned movement disorders presentations include:

  • Neuromelanin-sensitive MRI as a potential biomarker for Parkinson's
    Poster 114; March 15, 2018, 8:00 – 18:00 CET.
  • Wearable sensors for quantitative gait characteristics in clinical
    trials of Parkinson's disease.
    Poster 129; March 15, 2018, 8:00 –
    18:00 CET.
  • Efficacy and safety of BIIB092 in patients with progressive
    supranuclear palsy: PASSPORT Phase 2 study design.
    Session 18; March 17, 2018, 9:45 – 10:05 CET.

Biogen will participate in two panel discussions:

  • Forum discussion 2 – AD Phase III Clinical Trials. Panel
    Discussion; March 16, 2018, 14:25 – 15:25 CET.
  • Forum on novel approaches to disease-modifying therapies of
    Parkinson's disease (PD) and Lewy Body Disease (LBD).
    Discussion; March 17, 2018, 14:00 – 15:00 CET.

The "Importance of Early Identification and Treatment of Alzheimer's
disease" Plenary Session will be webcast live. To access the live
webcast, please visit the Investors section of Biogen's website at
An archived version of the webcast will be available following the

About Biogen
At Biogen, our mission is clear: we are
pioneers in neuroscience. Biogen discovers, develops, and delivers
worldwide innovative therapies for people living with serious
neurological and neurodegenerative diseases. Founded in 1978 as one of
the world's first global biotechnology companies by Charles Weissman,
Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert
and Phillip Sharp, today Biogen has the leading portfolio of medicines
to treat multiple sclerosis; has introduced the first and only approved
treatment for spinal muscular atrophy; and is focused on advancing
neuroscience research programs in Alzheimer's disease and dementia,
multiple sclerosis and neuroimmunology, movement disorders,
neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute
neurology. Biogen also manufactures and commercializes biosimilars of
advanced biologics.

We routinely post information that may be important to investors on our
website at To
learn more, please visit and
follow us on social media – TwitterLinkedInFacebookYouTube.

Biogen Safe Harbor
This press release contains
forward-looking statements made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995 about additional
results from the Phase 1b study of aducanumab, the potential clinical
effects of aducanumab and/or BIIB092, the identification and treatment
of Alzheimer's disease as well as clinical studies on Parkinson's
disease and progressive supranuclear palsy. These statements may be
identified by words such as "aim," "anticipate," "believe," "could,"
"estimate," "expect," "forecast," "intend," "may," "plan," "possible,"
"potential," "will" and other words and terms of similar meaning, and
are based on our current beliefs and expectations. You should not place
undue reliance on these statements or the scientific data presented.
Drug development and commercialization involve a high degree of risk,
and only a small number of research and development programs result in
commercialization of a product. Results in early stage clinical trials
may not be indicative of full results or results from later stage or
larger scale clinical trials and do not ensure regulatory approval.

These statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such statements,
including without limitation, the risk that we may not fully enroll our
clinical trials or enrollment will take longer than expected, unexpected
concerns may arise from additional data, analysis or results obtained
during our clinical trials, regulatory authorities may require
additional information or further studies, or may fail or refuse to
approve or may delay approval of our drug candidates, the occurrence of
adverse safety events, or we may encounter other unexpected hurdles. The
foregoing sets forth many, but not all, of the factors that could cause
actual results to differ from our expectations in any forward-looking
statement. Investors should consider this cautionary statement, as well
as the risk factors identified in our most recent annual or quarterly
report and in other reports filed with the Securities and Exchange
Commission. These statements are based on our current beliefs and
expectations and speak only as of the date of this press release. We do
not undertake any obligation to publicly update any forward-looking
statements, whether as a result of new information, future developments,
or otherwise.

View Comments and Join the Discussion!